Cardiol Therapeutics Inc.
CRDL
$1.41
$0.032.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.65% | 40.37% | 101.17% | 74.23% | 39.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.80% | 20.92% | 81.64% | 20.35% | 8.30% |
| Operating Income | 5.80% | -20.92% | -81.64% | -20.35% | -8.30% |
| Income Before Tax | 15.19% | -4.08% | -111.08% | 13.40% | -29.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.19% | -4.08% | -111.08% | 13.40% | -29.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.19% | -4.08% | -111.08% | 13.40% | -29.90% |
| EBIT | 5.80% | -20.92% | -81.64% | -20.35% | -8.30% |
| EBITDA | 5.20% | -20.73% | -82.69% | -20.76% | -8.32% |
| EPS Basic | 30.93% | 15.56% | -94.75% | 19.24% | -23.72% |
| Normalized Basic EPS | 30.96% | 15.61% | -95.09% | 19.19% | -23.87% |
| EPS Diluted | 30.93% | 15.56% | -94.75% | 19.24% | -23.72% |
| Normalized Diluted EPS | 30.96% | 15.61% | -95.09% | 19.19% | -23.87% |
| Average Basic Shares Outstanding | 22.82% | 23.39% | 8.30% | 7.25% | 4.94% |
| Average Diluted Shares Outstanding | 22.82% | 23.39% | 8.30% | 7.25% | 4.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |